Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial

Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus

(2021) Victoria P. Werth et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

(2020) P. Joly et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

(2019) James F. Howard et al.   NEUROLOGY

Pemphigus

(2019) Enno Schmidt et al.   LANCET

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

(2019) Adrian C. Newland et al.   AMERICAN JOURNAL OF HEMATOLOGY

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

(2019) L. J. Blumberg et al.   Science Advances

Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts

(2018) Dedee F. Murrell et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

(2018) Peter Ulrichts et al.   JOURNAL OF CLINICAL INVESTIGATION

Incidence and mortality of pemphigus in France

(2018) Lamia Jelti et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Rituximab as first-line treatment of pemphigus

(2017) Enno Schmidt   LANCET

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

(2017) Pascal Joly et al.   LANCET

Pemphigus

(2017) Michael Kasperkiewicz et al.   Nature Reviews Disease Primers

Management of Pemphigus Vulgaris

(2016) Mimansa Cholera et al.   ADVANCES IN THERAPY

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

(2013) N. Colliou et al.   Science Translational Medicine

Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up

(2012) Giuseppe Cianchini et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Immunoadsorption in Dermatology

(2012) Damian Meyersburg et al.   THERAPEUTIC APHERESIS AND DIALYSIS

High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study

(2010) G Chaidemenos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus

(2009) Misha Rosenbach et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

(2009) Masayuki Amagai et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

(2008) Dedee F. Murrell et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dependence of antibody-mediated presentation of antigen on FcRn

(2008) S.-W. Qiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA